Amneal Pharmaceuticals, Inc. announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr. Konidaris succeeds Todd Branning, who is no longer serving in this role, but remains available to the Company through March 31, 2020. Mr. Konidaris brings to Amneal more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics and data industries.

He most recently served as Chief Financial Officer and as a board member of Alcresta Therapeutics, Inc., a medical therapeutics company. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., a pharmaceutical company. Mr. Konidaris also previously served seven years as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation, as well as held various roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb.